A Phase 1/2 dose escalation and expansion study of TRI-611 in ALK-positive NSCLC

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2026
This article has no abstract
Epistemonikos ID: adb1a1c729f820bc7d9375da274c3269c007711b
First added on: Nov 01, 2026